GlaxoSmithKline (GSK) will provide combinations of molecules for screening via Plasticell’ s Combinatorial Cell Culture™ (CombiCult ® ) combinatorial stem cell screening technology, through a collaboration in whose value was not disclosed.
Plasticell will use the bead-based CombiCult platform to produce hematopoietic cells from induced pluripotent come cells (iPSCs) by optimizing the directed differentiation from the iPSCs to specific blood cell lineages for use simply by GSK in therapeutic research, the companies said.
CombiCult is made to allow for simultaneous screening of multiple iPSC lines, assisting the development of a robust protocol that is applicable across lines, Plasticell added.
“ During the course of developing its therapeutic programs, Plasticell has acquired considerable expertise in pluripotent and hematopoietic stem cells, the derivation of specific hematopoietic cellular types, and the use of small molecules to drive stem cellular differentiation, ” Plasticell founder and executive chairman Yen Choo, Ph. D., said in a statement. “ Furthermore,…